TY - JOUR
T1 - White and gray matter brain development in children and young adults with phenylketonuria
AU - Hawks, Zoë
AU - Hood, Anna M.
AU - Lerman-Sinkoff, Dov B.
AU - Shimony, Joshua S.
AU - Rutlin, Jerrel
AU - Lagoni, Daniel
AU - Grange, Dorothy K.
AU - White, Desirée A.
N1 - Funding Information:
The authors wish to thank the participants and families who generously participated in our research. We also thank Suzin Blankenship and Laurie Sprietsma for their contributions to study management, and Annie Lee, Maggie Clapp, Kelly Reger, Devante Morgan, and Amanda Namchuk for their assistance with data processing. Additionally, we would like to thank the physicians and staff of Washington University and Oregon Health & Science University who generously contributed to the study through recruitment and phenylalanine monitoring. This research was supported by the National Institute of Child Health and Human Development (R01HD044901 and U54HD087011). Computations were performed using facilities of the Washington University Center for High Performance Computing, which were partially provided through NIH grant S10 OD018091. During the study period, Anna Hood was supported in part by the National Heart, Lung, and Blood Institute (1F31HL134314-01) and Dov Lerman-Sinkoff was supported in part by the National Institute of Mental Health (F30MH109294). Zoë Hawks, Anna Hood, Jerrel Rutlin, Joshua Shimony, and Daniel Lagoni declare that they have no conflicts of interest. Desirée White and Dorothy Grange have received research grants from BioMarin Pharmaceutical Inc. and have served as consultants for BioMarin Pharmaceutical Inc. Dov Lerman-Sinkoff has received payment from an unrelated pharmaceutical company for use of his pet in veterinary product advertisements.
Funding Information:
Zoë Hawks, Anna Hood, Jerrel Rutlin, Joshua Shimony, and Daniel Lagoni declare that they have no conflicts of interest. Desirée White and Dorothy Grange have received research grants from BioMarin Pharmaceutical Inc. and have served as consultants for BioMarin Pharmaceutical Inc. Dov Lerman-Sinkoff has received payment from an unrelated pharmaceutical company for use of his pet in veterinary product advertisements.
Funding Information:
This research was supported by the National Institute of Child Health and Human Development ( R01HD044901 and U54HD087011 ). Computations were performed using facilities of the Washington University Center for High Performance Computing, which were partially provided through NIH grant S10 OD018091 . During the study period, Anna Hood was supported in part by the National Heart, Lung, and Blood Institute ( 1F31HL134314-01 ) and Dov Lerman-Sinkoff was supported in part by the National Institute of Mental Health ( F30MH109294 ).
Publisher Copyright:
© 2019
PY - 2019
Y1 - 2019
N2 - Phenylketonuria (PKU) is a recessive disorder characterized by disruption in the metabolism of the amino acid phenylalanine (Phe). Prior research indicates that individuals with PKU have substantial white matter (WM) compromise. Much less is known about gray matter (GM) in PKU, but a small body of research suggests volumetric differences compared to controls. To date, developmental trajectories of GM structure in individuals with PKU have not been examined, nor have trajectories of WM and GM been examined within a single study. To address this gap in the literature, we compared longitudinal brain development over a three-year period in individuals with PKU (n = 35; 18 male) and typically-developing controls (n = 71; 35 male) aged 7–21 years. Using diffusion tensor imaging (DTI) and structural magnetic resonance imaging (MRI), we observed whole-brain and regional WM differences between individuals with PKU and controls, which were often exacerbated with increasing age. In marked contrast with trajectories of WM development, trajectories of GM development did not differ between individuals with PKU and controls, indicating that neuropathology in PKU is more prominent in WM than GM. Within individuals with PKU, mediation analyses revealed that whole-brain mean diffusivity (MD) and regional MD in the corpus callosum and centrum semiovale mediated the relationship between dietary treatment compliance (i.e., Phe control) and executive abilities, suggesting a plausible neurobiological mechanism by which Phe control may influence cognitive outcomes. Our findings clarify the specificity, timing, and cognitive consequences of whole-brain and regional WM pathology, with implications for treatment and research in PKU.
AB - Phenylketonuria (PKU) is a recessive disorder characterized by disruption in the metabolism of the amino acid phenylalanine (Phe). Prior research indicates that individuals with PKU have substantial white matter (WM) compromise. Much less is known about gray matter (GM) in PKU, but a small body of research suggests volumetric differences compared to controls. To date, developmental trajectories of GM structure in individuals with PKU have not been examined, nor have trajectories of WM and GM been examined within a single study. To address this gap in the literature, we compared longitudinal brain development over a three-year period in individuals with PKU (n = 35; 18 male) and typically-developing controls (n = 71; 35 male) aged 7–21 years. Using diffusion tensor imaging (DTI) and structural magnetic resonance imaging (MRI), we observed whole-brain and regional WM differences between individuals with PKU and controls, which were often exacerbated with increasing age. In marked contrast with trajectories of WM development, trajectories of GM development did not differ between individuals with PKU and controls, indicating that neuropathology in PKU is more prominent in WM than GM. Within individuals with PKU, mediation analyses revealed that whole-brain mean diffusivity (MD) and regional MD in the corpus callosum and centrum semiovale mediated the relationship between dietary treatment compliance (i.e., Phe control) and executive abilities, suggesting a plausible neurobiological mechanism by which Phe control may influence cognitive outcomes. Our findings clarify the specificity, timing, and cognitive consequences of whole-brain and regional WM pathology, with implications for treatment and research in PKU.
KW - Brain
KW - Developmental trajectories
KW - Executive abilities
KW - Gray matter
KW - Phenylketonuria
KW - White matter
UR - http://www.scopus.com/inward/record.url?scp=85068548717&partnerID=8YFLogxK
U2 - 10.1016/j.nicl.2019.101916
DO - 10.1016/j.nicl.2019.101916
M3 - Article
C2 - 31491833
AN - SCOPUS:85068548717
SN - 2213-1582
VL - 23
JO - NeuroImage: Clinical
JF - NeuroImage: Clinical
M1 - 101916
ER -